Accelerated Approvals: How Recent Decisions will Impact Biotech's Future
Debate Sparked Over Recent Rulings, but What's Changed?
After 17 years of smooth sailing – Iressa (gefitinib, AstraZeneca plc) notwithstanding – the FDA's accelerated approval process seems to have hit some choppy waters.
